US › Healthcare

Editas Medicine Inc (EDIT)

US · Healthcare · Biotechnology

$2.77+4.53%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2.8M
Revenue YoY
-39.2%
Net profit
$-25.0M
Profit YoY
+67.2%
EPS
$-0.26
EPS estimate
$-0.24
Net margin
-882.4%

EPS came in at -0.26 against a street estimate of -0.24 — a miss of 8.3%.

Key statistics

Market cap
$395.9M
Forward P/E
0.0
P/B
89.47
Book value
$0.04
EPS (TTM)
$-1.14
52-week high
$4.54
52-week low
$1.66
50-day MA
$2.92
200-day MA
$2.64
Beta
2.10

Analyst view

Analysts rate Editas Medicine Inc a hold (5 buy, 8 hold, 2 sell out of 15) with an average price target of $5.78.

Shareholding

Insiders
0.17%
Institutions
49.44%

Largest institutional holders

FundStake
BlackRock Inc6.04%
Vanguard Group Inc5.35%
Vanguard Capital Management, LLC2.74%
Renaissance Technologies Corp2.59%
Vanguard Portfolio Management, LLC2.05%
Geode Capital Management, LLC1.51%
State Street Corp1.35%
Nuveen, LLC1.29%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Editas Medicine Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.